Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial

医学 安慰剂 内科学 胃肠病学 临床终点 C反应蛋白 纤维蛋白原 随机对照试验 肾脏疾病 随机化 炎症 病理 替代医学
作者
Yukihiro Wada,Camilla Jensen,Anna Sina P. Meyer,Amir Abbas Mohseni Zonoozi,Hirokazu Honda
出处
期刊:Journal of Cardiology [Elsevier BV]
卷期号:82 (4): 279-285 被引量:52
标识
DOI:10.1016/j.jjcc.2023.05.006
摘要

BACKGROUND: Despite optimal treatment, a residual inflammatory risk often remains in patients with atherosclerotic cardiovascular disease. In a US-based phase 2 trial, ziltivekimab, a fully human monoclonal antibody targeting the interleukin-6 ligand, significantly reduced biomarkers of inflammation compared with placebo in patients at high atherosclerotic risk. Here, we report the efficacy and safety of ziltivekimab in Japanese patients. METHODS: RESCUE-2 was a randomized, double-blind, 12-week, phase 2 trial. Participants aged ≥20 years with stage 3-5 non-dialysis-dependent chronic kidney disease and high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L were randomized to receive placebo (n = 13) or subcutaneous ziltivekimab 15 mg (n = 11) or 30 mg (n = 12) at Weeks 0, 4, and 8. The primary endpoint was percentage change in hsCRP levels from baseline to end of treatment (EOT; mean of Week 10 and Week 12 values). RESULTS: At EOT, median hsCRP levels were reduced by 96.2 % in the 15 mg group (p < 0.0001 versus placebo), by 93.4 % in the 30 mg group (p = 0.002 versus placebo), and by 27.0 % in the placebo group. Serum amyloid A and fibrinogen levels were also reduced significantly. Ziltivekimab was well tolerated and did not affect total cholesterol to high-density lipoprotein cholesterol ratios. There was a small, but statistically significant increase in triglyceride levels with ziltivekimab 15 mg and 30 mg compared with placebo. CONCLUSIONS: The efficacy and safety results support the development of ziltivekimab for secondary prevention and the treatment of patients at high atherosclerotic risk. CLINICALTRIALS: gov identifier, NCT04626505.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
理性悲歌完成签到,获得积分10
1秒前
beginer发布了新的文献求助10
2秒前
3秒前
4秒前
烟花应助CART汪采纳,获得10
5秒前
睿0924发布了新的文献求助10
5秒前
老实的机器猫完成签到,获得积分20
6秒前
张三发布了新的文献求助100
8秒前
科研通AI2S应助yulk采纳,获得10
8秒前
小蘑菇应助yhy采纳,获得10
9秒前
轮轮关注了科研通微信公众号
9秒前
10秒前
结实的秋凌完成签到,获得积分10
10秒前
10秒前
南炎发布了新的文献求助10
11秒前
梵天完成签到,获得积分10
11秒前
桐桐应助CGG采纳,获得10
11秒前
科研通AI6.2应助成太采纳,获得10
12秒前
小蘑菇应助科研通管家采纳,获得10
13秒前
今后应助科研通管家采纳,获得20
13秒前
爆米花应助科研通管家采纳,获得10
13秒前
eric888应助科研通管家采纳,获得150
13秒前
Orange应助科研通管家采纳,获得10
13秒前
我是老大应助科研通管家采纳,获得10
13秒前
13秒前
传奇3应助科研通管家采纳,获得10
13秒前
13秒前
乐空思应助科研通管家采纳,获得10
13秒前
13秒前
小二郎应助科研通管家采纳,获得10
13秒前
嗷大喵应助科研通管家采纳,获得30
13秒前
爆米花应助科研通管家采纳,获得10
14秒前
CipherSage应助科研通管家采纳,获得10
14秒前
完美世界应助科研通管家采纳,获得10
14秒前
科目三应助科研通管家采纳,获得30
14秒前
jshmech应助研友_8QxN1Z采纳,获得10
14秒前
14秒前
fionadong完成签到,获得积分10
15秒前
混子华完成签到,获得积分10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Les Mantodea de Guyane Insecta, Polyneoptera 2000
Leading Academic-Practice Partnerships in Nursing and Healthcare: A Paradigm for Change 800
Signals, Systems, and Signal Processing 610
Research Methods for Business: A Skill Building Approach, 9th Edition 500
Research Methods for Applied Linguistics 500
Picture Books with Same-sex Parented Families Unintentional Censorship 444
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6413302
求助须知:如何正确求助?哪些是违规求助? 8232252
关于积分的说明 17474103
捐赠科研通 5465991
什么是DOI,文献DOI怎么找? 2888112
邀请新用户注册赠送积分活动 1864835
关于科研通互助平台的介绍 1703108